In this short interview, Dr Scott Harris (Chief Medical Officer of AltImmune Inc.) joins us to discuss the emerging role of glucagon-containing dual and triple agonists for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). Dr Harris discusses the clinical need for these drugs, as well as an outline of the current evidence for the use of incretins in the treatment of obesity and MASH.

Interview Questions: 

1. What are the current unmet needs in treating obesity and MASH?
2. What is the current evidence for incretins in the treatment of obesity and MASH?
3. What further research is needed?
4. What are the challenges and opportunities in implementing this into clinical practice?

Recorded remotely from Maryland, 2024.